08:00 , Feb 15, 2010 |  BC Week In Review  |  Company News

Mondobiotech, United Therapeutics deal

United Therapeutics' Lung Rx LLC subsidiary received a license to develop and commercialize Mondobiotech's Aviptadil. Lung Rx said it will focus development of the vasoactive intestinal peptide (VIP) on pulmonary arterial hypertension (PAH), sarcoidosis, idiopathic...
08:00 , Jan 11, 2010 |  BioCentury  |  Strategy

Evolution of Biogen Idec's Pipeline

Evolution of Biogen Idec's Pipeline...
07:00 , May 26, 2008 |  BC Week In Review  |  Clinical News

Aviptadil: Phase II data

In the Phase II AVICUTE trial in 20 patients, compared with baseline, a single 100 µg dose of Aviptadil significantly reduced pulmonary artery pressure by 5.0% and pulmonary vascular resistance by 7.8% (p<0.05 for both)....
07:00 , Aug 20, 2007 |  BioCentury  |  Product Development

Blast from the past

Biogen Idec Inc. announced plans to dust off its Adentri program and move into Phase III testing next year with the adenosine A1 receptor antagonist. The company hopes that Adentri may avoid issues with seizures...
07:00 , Jul 9, 2007 |  BC Week In Review  |  Company News

Biogen Idec, Cardiokine deal

BIIB and Cardiokine partnered to develop and commercialize Cardiokine's lixivaptan to treat hyponatremia. Cardiokine will receive $50 million up front and is eligible for $170 million in milestones, plus royalties. BIIB and Cardiokine will share...
08:00 , Jan 15, 2007 |  BioCentury  |  Strategy

Specialty plays

Rather than sticking to its bread-and-butter disease areas of immunology, neurology and oncology, Biogen Idec Inc. has decided the best way to grow its pipeline is to look for external opportunities in niche markets. In...
07:00 , Oct 16, 2006 |  BC Week In Review  |  Clinical News

Aviptadil: Completed Phase II enrollment

mondoBIOTECH completed enrollment and treatment of 10 patients in the open-label, German Phase II AVISARCO trial. Patients received 200 µg of inhaled Aviptadil daily for 4 weeks. mondoBiotech AG , Basel, Switzerland   Product: Aviptadil...
07:00 , Sep 18, 2006 |  BC Week In Review  |  Company News

Biogen Idec, mondoBiotech AG deal

mondoBiotech granted BIIB an exclusive worldwide license to develop, manufacture and commercialize Aviptadil to treat pulmonary arterial hypertension (PAH). The vasoactive intestinal peptide is in Phase II testing for PAH. BIIB expects to start a...
07:00 , Sep 18, 2006 |  BioCentury  |  Product Development

Getting the VIP treatment

Tantalized by early Phase II data in 2003, Biogen Idec Inc. waited until last week to obtain worldwide rights to mondoBiotech AG's aviptadil vasoactive intestinal peptide (VIP) to treat pulmonary arterial hypertension based on a...
07:00 , Sep 18, 2006 |  BioCentury  |  Product Development

PAH data comparison

PAH data comparison...